Press Releases

Press Releases

Mar 10, 2020
CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1 Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials Phase 1 clinical trial expected to initiate in late spring of 2020 GAITHERSBURG, Md....
Feb 26, 2020
Vaccine candidate derived from coronavirus spike (S) protein Matrix-M™ adjuvant expected to boost immune responses Phase 1 clinical trial planned for late spring GAITHERSBURG, Md. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing...
Jan 15, 2020
GAITHERSBURG, Md. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for...
Jan 09, 2020
GAITHERSBURG, Md. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference ....
Nov 07, 2019
NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company...
Sep 19, 2019
GAITHERSBURG, Md. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the Ladenburg...
Displaying 41 - 50 of 192